Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing ...

The S&P500 (SP500)closed in the red, after the week witnessed muted inflation data, a court striking down President Trump's ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The S&P 500 (^GSPC) logged its best May since 1990 and its best month since Nov. 2023, rising over 6%, while the Dow (^DJI) ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Tech stocks drag Nasdaq lower as soft PCE data boosts Fed rate cut hopes. Traders brace for June’s tariff rulings and policy ...